Core Viewpoint - The stock of Gilead Sciences-B (01672) experienced a decline of 9.64%, trading at 16.5 HKD per share with a transaction volume of 883 million HKD as of 09:30 on August 19 [1] Group 1: Company Overview - Gilead Sciences is an innovative research-driven biotechnology company focused on the development, production, and commercialization of new drugs in three main medical fields: viral diseases, non-alcoholic fatty liver disease, and oncology [1] - The company has a production base of approximately 17,000 square meters located in Shaoxing Binhai New City, Zhejiang, with an annual designed production capacity of 130 million tablets [1] - Gilead Sciences has multiple drugs in the research pipeline and has obtained drug production licenses [1] Group 2: Financial Performance - As of the mid-year report in 2025, Gilead Sciences reported total revenue of 1.081 million HKD and a net loss of 87.951 million HKD [2]
歌礼制药-B(01672)下跌9.64%，报16.5元/股